Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study

医学 贝伐单抗 彭布罗利珠单抗 肿瘤科 化疗 危险系数 实体瘤疗效评价标准 内科学 外科 癌症 进行性疾病 免疫疗法 置信区间
作者
D. Lorusso,Nicoletta Colombo,Coraline Dubot,M.V. Cáceres,Kazuki Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,A. Arkhipov,Ka Wan Li,S. Toker,Çağla Tekin,Krishnansu S. Tewari,B.J. Monk
出处
期刊:Annals of Oncology [Elsevier BV]
被引量:6
标识
DOI:10.1016/j.annonc.2024.10.002
摘要

HIGHLIGHTS•This exploratory analysis of KEYNOTE-826 examined treatment outcomes in patient subgroups defined by bevacizumab (beva) use•Pembrolizumab+chemotherapy improved progression-free survival and overall survival vs placebo+chemotherapy in all subgroups•The safety profile of pembrolizumab+chemotherapy±beva was manageable•Results support use of pembrolizumab+chemotherapy±beva for persistent, recurrent, or metastatic cervical cancerABSTRACTBackgroundIn KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (± bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use.Patients and methodsEligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1:1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (± bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% CIs were based on a stratified Cox regression model.Results617 patients were randomized (pembrolizumab arm, n=308 [63.6% with bevacizumab]; placebo arm, n=309 [62.5% with bevacizumab]). The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the PD-L1 combined positive score (CPS) ≥1 (0.56 [0.43−0.73]) and all-comer (0.57 [0.45−0.73]) populations; OS results were 0.60 (0.45−0.79) and 0.61 (0.47−0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the PD-L1 CPS≥1 (0.61 [0.44−0.85]) and all-comer (0.69 [0.50−0.94]) populations; OS results were 0.61 (0.44−0.85) and 0.67 (0.49−0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm.ConclusionPembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
诚心的初露完成签到,获得积分10
2秒前
lyb完成签到 ,获得积分10
4秒前
风中方盒完成签到,获得积分20
4秒前
布丁圆团完成签到,获得积分10
5秒前
yikeshu完成签到,获得积分10
5秒前
Zoe完成签到 ,获得积分10
6秒前
8秒前
星辰大海应助do0采纳,获得10
9秒前
tt完成签到 ,获得积分10
10秒前
浅辰完成签到,获得积分10
11秒前
大气萤完成签到,获得积分20
12秒前
12秒前
我ppp完成签到 ,获得积分10
12秒前
13秒前
易燃物品完成签到,获得积分10
13秒前
Hello应助Ther采纳,获得10
15秒前
CherylZhao完成签到,获得积分10
16秒前
Galato发布了新的文献求助10
17秒前
颜愫完成签到,获得积分10
17秒前
安详向日葵完成签到 ,获得积分10
18秒前
拼搏的白云完成签到,获得积分10
18秒前
852应助hhh采纳,获得10
18秒前
李白白白完成签到,获得积分10
18秒前
王手完成签到,获得积分10
18秒前
19秒前
一人完成签到,获得积分10
20秒前
do0完成签到,获得积分10
21秒前
yar应助xlz110采纳,获得10
21秒前
NexusExplorer应助落寞凌波采纳,获得10
23秒前
量子星尘发布了新的文献求助10
26秒前
123完成签到 ,获得积分10
26秒前
哈哈呵完成签到,获得积分10
26秒前
26秒前
Rylee完成签到,获得积分10
26秒前
Jiro完成签到,获得积分10
28秒前
我ppp发布了新的文献求助60
29秒前
30秒前
纳米酶催化完成签到,获得积分10
31秒前
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029